Novotech Selects Oracle’s Siebel Clinical Trial Management
China’s evolving regulatory reforms have greatly impacted review and approval timelines, streamlined processes, and expedited the development of innovative drugs.
TheraVida Initiates Phase 2 Trial of THVD-201 for Overactive Bladder and Urina
Media Release 27 August 2021
NOVOTECH CRO EXPANDS ASIA REGION SERVICES WITH NEW CHINA OFFICE IN SHANGHAI
Taipei, 7 September 2021
This webinar looks at Asia’s rare disease clinical trial landscape, why China is an increasingly attractive location for rare disease trials and critical program strategies to consider.
Sydney-based Novotech today (January 15) announced that it has expanded its Hong Kong operation into a permanent office with more staff t
BIOMETRICS AT NOVOTECH WE HAVE EXPERIENCE ACROSS A BROAD RANGE OF THERAPEUTIC AREAS AND ALL PHASES OF THE D
In 2020, Globocan reported over 400,000 new corpus uteri cases, with Asia accounting for about 40% of these new cases. China, where EC is the third most common female malignancy, accounted for nearly half of the new cases in Asia.
Diabetes, which is endemic in most Western countries, is now seeing a surge in developing nations across Asia due to aging, urbanization, and changing dietary habits. It is estimated that about 80% of the people with diabetes now reside in developing countries, and mortality rates due to diabetes are higher in the Asia-Pacific compared to the rest of the world.
Novotech Selects Oracle’s Siebel Clinical Trial Management System to Support Continued Growth
Hong Kong - Novotech, a leading biotech specialist CRO in the Asia-Pacific region this month showcases its rare diseases
HAVE YOU EVER WONDERED WHAT A CAREER IN CLINICAL DATA MANAGEMENT WOULD BE LIKE? Well, we caught up with a few Data Managers fro